Equities research analysts expect that Dyne Therapeutics, Inc. (NASDAQ:DYN) will announce earnings of ($0.99) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Dyne Therapeutics’ earnings, with estimates ranging from ($1.06) to ($0.86). Dyne Therapeutics posted earnings of ($0.64) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 54.7%. The firm is scheduled to report its next earnings report on Thursday, March 3rd.
On average, analysts expect that Dyne Therapeutics will report full-year earnings of ($2.91) per share for the current year, with EPS estimates ranging from ($2.99) to ($2.78). For the next year, analysts anticipate that the firm will post earnings of ($3.76) per share, with EPS estimates ranging from ($4.67) to ($3.06). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Dyne Therapeutics.
Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, November 4th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.19).
DYN traded up $0.13 during trading on Friday, hitting $9.29. 394,243 shares of the stock were exchanged, compared to its average volume of 183,254. The firm has a market capitalization of $478.70 million, a P/E ratio of -3.64 and a beta of 0.02. Dyne Therapeutics has a 1-year low of $8.34 and a 1-year high of $32.31. The stock has a fifty day moving average price of $13.08 and a two-hundred day moving average price of $15.64.
A number of large investors have recently made changes to their positions in DYN. UBS Asset Management Americas Inc. purchased a new position in Dyne Therapeutics in the third quarter valued at about $198,000. Bank of New York Mellon Corp increased its position in Dyne Therapeutics by 4.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 405,262 shares of the company’s stock valued at $6,582,000 after acquiring an additional 15,654 shares during the period. Two Sigma Advisers LP boosted its stake in Dyne Therapeutics by 5.8% during the 3rd quarter. Two Sigma Advisers LP now owns 27,400 shares of the company’s stock valued at $445,000 after purchasing an additional 1,500 shares in the last quarter. Two Sigma Investments LP bought a new position in Dyne Therapeutics during the 3rd quarter valued at $1,838,000. Finally, Point72 Asset Management L.P. boosted its stake in shares of Dyne Therapeutics by 21.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 827,000 shares of the company’s stock worth $13,430,000 after acquiring an additional 146,100 shares in the last quarter. Institutional investors own 67.06% of the company’s stock.
Dyne Therapeutics Company Profile
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Article: What is the outlook for the FAANG stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.